The Market Reports

Synopsis
TNF (tumor necrosis factor) inhibitors are anti-inflammatory drugs. TNF inhibitors help to block the TNF alpha that occurs naturally in the body and causes inflammation. TNF drugs are used to reduce inflammation and stop disease progression by targeting the tumor necrosis factor, which is an inflammation-causing substance. TNF inhibitor drugs are employed to treat inflammatory conditions such as rheumatoid arthritis and juvenile arthritis. Generally, in the healthy person, the TNF levels remain steady. However, in a patient with rheumatoid arthritis, the level of TNF is increasing which leads to more inflammation. TNF inhibitor drugs act as blockers for TNF substances. TNF alpha blockers are highly effective in the treatment of patients with active rheumatoid arthritis. These drugs are used in patients as a conventional second-line treatments.
The global TNF Inhibitors market size is expected to reach US$ 45750 million by 2029, growing at a CAGR of 1.1% from 2023 to 2029. The market is mainly driven by the significant applications of TNF Inhibitors in various end use industries. The expanding demands from the Skin Disease, Ankylosing Spondylitis, Gastrointestinal Disease and Rheumatoid Arthritis, are propelling TNF Inhibitors market. Monotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Combination Therapy segment is estimated at % CAGR for the next seven-year period.
The adalimumab segment is likely to expand at a significant pace during the forecast period. The drug is effectively used in a broad range of pain management therapies and is widely available over the counter. Based on distribution channel, the TNF inhibitors market can be segmented into hospital pharmacy and retail pharmacy. The hospital pharmacy segment is likely to expand at a significant pace between 2017 and 2025, this is because patients with rheumatoid arthritis, arthritis give more preference to the hospitals for treatment. Increase in elderly population and rise in the prevalence of rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease are some of the factors that drive the TNF inhibitors market. According to the National Health Interview Survey, in 2016, almost 20% of the global population was reported to be suffering from chronic pain, with rheumatoid arthritis being one of the major reasons. Moreover, according to the Center for Disease Control and Prevention, by 2040, approximately 78 million (26%) of the U.S. adults are projected to have arthritis. Owing to this, the consumption of TNF inhibitor dugs is likely to increase rapidly in the near future. However, side-effects associated with the use of TNF inhibitor drugs such as skin irritation, flushing, headache, and abdominal pain are estimated to hinder the market in the next few years.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for TNF Inhibitors, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global TNF Inhibitors market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global TNF Inhibitors market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, TNF Inhibitors sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of TNF Inhibitors covered in this report include Pfizer, Novartis, Boehringer Ingelheim, Amgen, BioPharma, Mochida Pharmaceutical and Hanall, etc.
The global TNF Inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Novartis
Boehringer Ingelheim
Amgen
BioPharma
Mochida Pharmaceutical
Hanall
Global TNF Inhibitors market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global TNF Inhibitors market, Segment by Type:
Monotherapy
Combination Therapy
Global TNF Inhibitors market, by Application
Skin Disease
Ankylosing Spondylitis
Gastrointestinal Disease
Rheumatoid Arthritis
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of TNF Inhibitors companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion

Index